GLP-1 Weight Loss Projection
See projected weight loss based on published clinical trial data from STEP and SURMOUNT studies. These are average results — individual outcomes vary.
Clinical Trajectory
| Treatment Week | Month | % Reduction | Weight (lbs) |
|---|---|---|---|
| Wk 4 | Month 1 | -2% | 215.6 |
| Wk 12 | Month 3 | -6% | 206.8 |
| Wk 20 | Month 5 | -10.6% | 196.7 |
| Wk 28 | Month 6 | -12% | 193.6 |
| Wk 36 | Month 8 | -13% | 191.4 |
| Wk 52 | Month 12 | -14.5% | 188.1 |
| Wk 68 | Month 16 | -14.9% | 187.2 |
| Wk 72 | Month 17 | -14.9% | 187.2 |
Population Outcomes (STEP 1)
Type 2 diabetes affects results
People with T2D typically lose less weight on the same medications. Semaglutide 2.4 mg: -14.9% (no T2D) vs -9.6% (T2D). Tirzepatide 15 mg: -22.5% vs -14.7%.
These are averages
Individual results vary significantly. In STEP 1, ~32% of people lost 20%+ while ~14% lost less than 5%. Diet, exercise, and genetics all play a role.
Weight loss isn't linear
You'll lose fastest in months 1-3, then slow gradually. Most people plateau between weeks 52-68. This is normal — the medication is still working.
Stopping means regain
In STEP 1, people who stopped semaglutide regained about two-thirds of lost weight within a year. These medications typically require ongoing use.
Ready to start? Get matched with a vetted provider.
The right provider will help you pick the best medication for your goals, manage your titration, and monitor your progress.
Find My Provider